These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

89 related items for PubMed ID: 407391

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Critical concentrations for resistances of tubercle bacilli to tuberactinomycin-N, viomycin, capreomycin, and lividomycin in patients treated with these agents (cross-resistance-relationships among resistances to aminoglucoside-antibiotics found during chemotherapy for tuberculosis) (author's transl)].
    Tsukamura M, Mizuno S, Murata H, Oshima T.
    Kekkaku; 1975 May; 50(4-5):123-30. PubMed ID: 49449
    [No Abstract] [Full Text] [Related]

  • 4. Susceptibility of south Indian strains of Mycobacterium tuberculosis to tuberactinomycin.
    Selvakumar N, Kumar V, Acharyulu GS, Rehman F, Paramasivan CN, Prabhakar R.
    Indian J Med Res; 1992 May; 95():101-4. PubMed ID: 1506058
    [Abstract] [Full Text] [Related]

  • 5. [Antibacterial activity of enviomycin for atypical mycobacteria. 1. Antibacterial activity in vitro (author's transl)].
    Toyohara M.
    Kekkaku; 1978 Apr; 53(4):255-60. PubMed ID: 661057
    [No Abstract] [Full Text] [Related]

  • 6. [Clinical study on tuberactinomycin-N (TUM-N) and viomycin (VM) in retreatment of pulmonary tuberculosis (author's transl)].
    Kekkaku; 1974 Jul; 49(7):207-15. PubMed ID: 4372439
    [No Abstract] [Full Text] [Related]

  • 7. [Studies on tuberactinomycin-N. Report 3. Comparison of the effects of TUM-N and INH on experimental mouse tuberculosis (author's transl)].
    Shimizu T, Yokoyama M, Yoshida U, Onuma H, Narita A.
    Kekkaku; 1977 Jan; 52(1):21-7. PubMed ID: 839648
    [No Abstract] [Full Text] [Related]

  • 8. Chemical studies on tuberactinomycin. VIII. Isolation of tuberactinamine N, the cyclic peptide moiety of tuberactinomycin N, and conversion of tuberactinomycin N to O.
    Wakamiya T, Shiba T.
    J Antibiot (Tokyo); 1975 Apr; 28(4):292-7. PubMed ID: 808523
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Cross resistance of tubercle bacilli to KM, VM, CPM, LVM, and TUM. II. The susceptibility of antibiotic-resistant strains which were obtained in vitro to the five antibiotics (author's transl)].
    Saito T, Fukuhara Y.
    Kekkaku; 1974 Apr; 49(4):91-6. PubMed ID: 4137393
    [No Abstract] [Full Text] [Related]

  • 11. [Drug resistance of tubercle bacilli -- from the clinical point of view (author's transl)].
    Fukuhara Y.
    Kekkaku; 1976 Dec; 51(12):477-87. PubMed ID: 65494
    [No Abstract] [Full Text] [Related]

  • 12. [The effects of tuberactinomycin-N (TUM-N) for severe pulmonary tuberculosis (author's transl)].
    Miwa T, Tsukamura M, Majima T, Ando Y, Kotetsu Y.
    Kekkaku; 1975 Aug; 50(8):229-33. PubMed ID: 1195529
    [No Abstract] [Full Text] [Related]

  • 13. [Experimental studies in vitro on the antituberculous activities of 27753 (R.P), a semisynthetic derivative of griselimycine. II. Antituberculous activities of R.P. in combination with other antituberculous agents].
    Shibata A.
    Bull Chest Dis Res Inst Kyoto Univ; 1984 Mar; 17(1-2):32-7. PubMed ID: 6442173
    [No Abstract] [Full Text] [Related]

  • 14. [Experimental studies in vitro on the antituberculous activities of 27753RP (R.P), a semisynthetic derivative of griselimycine. I. Antituberculous activities of R.P examined at intermittent, short time and continuous exposure in vitro].
    Shibata A.
    Bull Chest Dis Res Inst Kyoto Univ; 1984 Mar; 17(1-2):26-31. PubMed ID: 6442172
    [No Abstract] [Full Text] [Related]

  • 15. [Experimental studies in vitro on the antituberculous activities of 27753RP (R.P), a semisynthetic derivative of griselimycine. IV. Antituberculous activities of R.P in vitro under various inadequate conditions for the growth of tubercle bacilli].
    Shibata A.
    Bull Chest Dis Res Inst Kyoto Univ; 1984 Mar; 17(1-2):43-9. PubMed ID: 6442175
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cross-resistant relationships among the aminoglucoside antibiotics in Mycobacterium tuberculosis.
    Tsukamura M, Mizuno S.
    J Gen Microbiol; 1975 Jun; 88(2):269-74. PubMed ID: 50402
    [Abstract] [Full Text] [Related]

  • 18. Localization of co-resistance to streptomycin, kanamycin, capreomycin, and tuberactinomycin in core particles derived from ribosomes of viomycin-resistant Mycobacterium smegmatis.
    Yamada T, Mizuguchi Y, Suga K.
    J Antibiot (Tokyo); 1976 Oct; 29(10):1124-6. PubMed ID: 62857
    [No Abstract] [Full Text] [Related]

  • 19. [Experimental studies in vitro on the antituberculous activities of 27753RP (R.P), a semisynthetic derivative of griselimycine. III. Cross resistance of R.P].
    Shibata A.
    Bull Chest Dis Res Inst Kyoto Univ; 1984 Mar; 17(1-2):38-42. PubMed ID: 6442174
    [No Abstract] [Full Text] [Related]

  • 20. Experimental and clinical study on the antituberculous activity of tuberactinomycin-N, a new antibiotic.
    Toyoara M.
    Bull Int Union Tuberc; 1974 Aug; 49 suppl 1():288-91. PubMed ID: 4468026
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.